Atypical antipsychotic drugs improve cognition in schizophrenia (Q44297747)

1 December 2017

Atypical antipsychotic drugs improve cognition in schizophrenia (English)

1 reference

1 December 2017

0 references

Herbert Y Meltzer

1

1 reference

PubMed ID

12559661

1 December 2017

Tomiki Sumiyoshi

series ordinal

2

1 reference

PubMed ID

12559661

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

Biological Psychiatry

1 reference

1 December 2017

53

1 reference

1 December 2017

3

1 reference

1 December 2017

265-7; author reply 267-8

1 reference

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Another view of therapy for cognition in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Placebo-controlled trial of glycine added to clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

D-serine added to antipsychotics for the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Does cognitive function improve with quetiapine in comparison to haloperidol?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901790-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(02)01790-0

1 reference

1 December 2017

1 reference

PubMed ID

12559661